Choong Ang Vaccine Laboratories (CAVAC)

What Choong Ang Vaccine Laboratories (CAVAC) does

Choong Ang Vaccine Laboratories (CAVAC) is a South Korea-based animal vaccine manufacturer founded in 1968 in Daejeon and listed on KOSDAQ since 2003. The company develops, manufactures, and commercializes approximately 80 veterinary vaccine products organized into species-specific sub-brands: SuiShot (swine), PoulShot (poultry), BoviShot (cattle), CaniShot (dogs), FeliShot (cats), AquaShot (aquaculture), and LabiShot (rabbits). CAVAC claims the No. 1 position in Korea's domestic animal vaccine market and supplies products to more than 20 export markets including China, Brazil, Russia, Vietnam, the Philippines, Egypt, and India. The company was the first Korean animal vaccine producer to obtain KVGMP approval (1993) and has subsequently passed GMP audits from Bayer HealthCare and the Egyptian government, supporting international regulatory clearance.

Name

Choong Ang Vaccine Laboratories (CAVAC)

Legal name

주식회사 중앙백신연구소 | Choong Ang Vaccine Laboratories Co.,Ltd.

Website

https://cavac.co.kr

Company type

Public

Founded year

1968

Operating status

Operating

Headcount range

101–250 employees

Short description

CAVAC is a South Korean animal vaccine manufacturer (founded 1968, KOSDAQ-listed) producing roughly 80 vaccines for livestock, companion animals, and wildlife, supplying domestic farms, government agencies, and 20-plus export markets.

Ownership category

akta.pro rank

Product category

Animal Vaccines

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA), Wildlife & Zoo/Exotic Animal Vaccines (HLAMAKAG), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Animal vaccines
• Veterinary biologics
• Livestock vaccines
• Poultry vaccines
• Swine vaccines

Headquarters

HQ city

Daejeon

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Animal Vaccine Sales (Domestic Korea): CAVAC generates the majority of its revenue from domestic sales of approximately 80 animal vaccines across livestock (swine, poultry, cattle, fish, rabbits), companion animal (dogs, cats), and wildlife segments. Revenue in 2024 was KRW 45.59 billion (approx. USD 33.5 million at 1,360 KRW/USD).
2. International Vaccine Export: CAVAC exports animal vaccines to over 20 countries including China, Brazil, Russia, Vietnam, the Philippines, Egypt, and others, generating foreign export revenue. The company holds product registrations and distribution contracts in key markets and has achieved the '10 Million Dollar Export Tower' award from KITA.
3. Government / Public Procurement: CAVAC supplies vaccines through the Korea National Defense Procurement Agency (조달청) for national animal disease control and eradication programs, including rabies control and classical swine fever management.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

CAVAC develops, manufactures, and sells approximately 80 animal vaccines spanning livestock (swine, poultry, cattle, fish, rabbits), companion animals (dogs, cats), and wildlife. Products are organized under species-specific brands (SuiShot®, PoulShot®, BoviShot®, CaniShot®, FeliShot®, AquaShot®, LabiShot®) and include inactivated, live attenuated, marker (DIVA), and oral bait vaccine platforms. The company supplies the South Korean domestic market through direct sales and government procurement, and exports to more than 20 countries via distributor partnerships.

Product overview

CAVAC operates as an animal vaccine specialist offering a multi-brand, species-specific product portfolio. The company produces approximately 80 vaccine products across distinct sub-brands organized by animal type: SuiShot® (swine vaccines including PCV2, PED, classical swine fever), PoulShot® (poultry vaccines for avian influenza, Newcastle disease, infectious bronchitis), BoviShot® (cattle vaccines for brucellosis, IBR, BVD), CaniShot® (companion animal/dog vaccines for distemper, rabies, kennel cough), FeliShot® (cat vaccines for panleukopenia, rhinotracheitis), AquaShot® (aquaculture vaccines for fish), and LabiShot® (rabbit vaccines). Products range from single-disease vaccines to multi-valent combination vaccines. CAVAC also develops custom autogenous vaccines for specific farm operations and exports to over 20 countries globally.

Differentiator

Problem solved

Functional benefit

Brands

• SuiShot®: Porcine (swine) vaccine brand including SuiShot® Circo-ONE, SuiShot® CSFM-B, and other swine vaccines.
• PoulShot®
• BoviShot®
• CaniShot®
• FeliShot®
• AquaShot®
• X-Series
• 래비샷® (Rabyshot®)

Products and services

• SuiShot® (Swine Vaccines) SuiShot® is CAVAC's flagship swine vaccine brand providing protection against porcine circovirus type 2 (PCV2), classical swine fever, porcine epidemic diarrhea (PED), and other major swine diseases. Key products include SuiShot® Circo-ONE (PCV2 inactivated vaccine) and SuiShot® CSFM-B (classical swine fever marker vaccine). Targeted at swine farms, integrators, and government disease control programs.
• PoulShot® (Poultry Vaccines) PoulShot® is CAVAC's poultry vaccine brand providing protection against avian influenza, Newcastle disease, infectious bronchitis, Gumboro disease, and other avian diseases affecting chickens, ducks, and other poultry. Targeted at poultry farms, integrators, and government avian disease control programs.
• BoviShot® (Cattle Vaccines) BoviShot® is CAVAC's cattle vaccine brand offering protection against bovine brucellosis, IBR, BVD, bovine rotavirus and coronavirus infections, Akabane disease, and other cattle diseases. Targeted at cattle farms and dairy operations.
• CaniShot® (Canine Vaccines) CaniShot® is CAVAC's canine vaccine brand providing protection against distemper, parvovirus, rabies, canine influenza (H3N2), kennel cough, and other canine diseases. Targeted at veterinary clinics and pet owners.
• FeliShot® (Feline Vaccines) FeliShot® is CAVAC's feline vaccine brand offering protection against feline panleukopenia, viral rhinotracheitis, and feline calicivirus infection. Targeted at veterinary clinics and cat owners.
• AquaShot® (Aquaculture Vaccines) AquaShot® is CAVAC's aquaculture vaccine brand providing protection against bacterial infections in farmed fish, including streptococcosis in olive flounder. Targeted at fish farms and aquaculture operations.
• LabiShot® (Rabbit Vaccines) LabiShot® is CAVAC's rabbit vaccine brand providing protection against rabbit viral hemorrhagic disease. Targeted at rabbit farming operations.
• Wildlife Oral Bait Vaccines Oral bait vaccines for wildlife disease control, including the SuiShot® Classical Swine Fever Marker Live Bait Vaccine for wild boar and rabies bait vaccine for raccoons. Targeted at government animal health agencies and wildlife management programs.
• X-Series (PED-X Live, PED-X) X-Series is CAVAC's newer swine vaccine product line targeting Porcine Epidemic Diarrhea (PED), including PED-X Live (live attenuated vaccine) and PED-X. Targeted at swine farms requiring protection against PED outbreaks.
• Autogenous / Custom Vaccines Custom autogenous vaccines manufactured for specific farm pathogens that are not addressed by commercial vaccines, such as swine pleuropneumonia + pasteurellosis combinations and poultry E. coli autogenous vaccines. Targeted at livestock farms with pathogen-specific disease challenges requiring farm-customized solutions.

Quantifiable outcome

• Korea's No. 1 animal vaccine manufacturer with the largest domestic market share
• +3 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and major.

• Elanco Animal HealthcoreChannel Partner/ Reseller/ Distributor · 1 January 2023Elanco Animal Health and CAVAC entered into a distribution agreement for CAVAC's SuiShot® (Circo-ONE) and related products in China and Brazil. CAVAC completed product registration and the partnership was formalized in 2023. This is a key strategic partnership for CAVAC's international expansion in the world's largest swine markets.
• Bayer HealthCare (Animal Health Division)majorTechnology or Integration · 1 January 2018CAVAC successfully passed Bayer HealthCare's global GMP audit, validating its manufacturing quality standards at par with international pharmaceutical company requirements. CAVAC commenced exports to Bayer Vietnam in 2014 following the audit.
• Egyptian Government (General Organization for Veterinary Services)majorChannel Partner/ Reseller/ Distributor · 1 January 2017CAVAC passed the Egyptian government's GMP inspection, enabling it to supply animal vaccines to the Egyptian market. Egypt represents a significant market for poultry and livestock vaccines in the Middle East and Africa region.
• Russian Regulatory AuthoritiescoreChannel Partner/ Reseller/ Distributor · 1 January 2016CAVAC obtained regulatory approval to export animal vaccines to Russia, one of the world's largest livestock markets. This followed entry into Russian, Nigerian, and Bahraini markets in 2016.
• Bayer VietnammajorChannel Partner/ Reseller/ Distributor · 1 January 2014CAVAC commenced direct export of animal vaccines to Bayer Vietnam, leveraging Bayer's distribution network in Southeast Asia's veterinary pharmaceutical market.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• HIPRA: Spanish veterinary biopharmaceutical company specializing in animal vaccines for swine, poultry, cattle and companion animals. Closely comparable in scale and focus to CAVAC, and a direct competitor in European and Latin American markets.
• Bioveta: Czech veterinary vaccine manufacturer producing livestock and companion animal vaccines with established export presence in Eastern Europe, Asia and the Middle East. Similar in scale and product mix to CAVAC and competes in overlapping emerging markets.
• Phibro Animal Health: US-listed mid-market animal health company focused on vaccines, nutritionals and pharmaceuticals for livestock and poultry. Similar scale to CAVAC and directly comparable as a smaller, regionally-focused competitor in the global animal vaccine space.
• Elanco Animal Health: Global animal-health company and CAVAC's distribution partner for SuiShot® in China and Brazil. Competes in the same swine and poultry vaccine categories and represents both a near-term growth channel and a long-term competitive risk.
• IDT Biologika: German animal vaccine manufacturer with strong livestock and wildlife oral bait vaccine capabilities. Directly comparable to CAVAC's classical swine fever marker and wildlife rabies bait vaccine offerings.

Broad incumbents

• Merck Animal Health: Major animal vaccine manufacturer with strong swine, poultry, cattle and companion animal portfolios globally. Overlaps with CAVAC in PCV2, PED, AI and rabies vaccines and competes for the same Korean and emerging-market accounts.
• Zoetis: Global leader in animal health and vaccines, including swine, poultry, cattle and companion animal vaccines. Directly comparable in product categories (PCV2, AI, CSF) but vastly larger and broader, making it both a competitor and a benchmark for CAVAC's international ambitions.
• Virbac: French animal health company with a broad veterinary vaccine and pharmaceutical portfolio across companion animals, livestock and aquaculture. Comparable in species breadth and product mix, though larger and more globally diversified.
• Boehringer Ingelheim Animal Health: One of the largest animal vaccine players globally, particularly strong in swine (PRRS, PCV2) and poultry. Directly comparable to CAVAC's SuiShot® and PoulShot® franchises and competes in many of CAVAC's target export markets.

Regional players

• Jinyu Biotechnology (Ringpu Bio): One of China's largest animal vaccine companies with a portfolio spanning swine, poultry and companion animals. Regionally focused on China and a direct competitor in the swine vaccine market where CAVAC's Elanco partnership targets entry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCwCtR069UD4ozZi1LBeNBUg
• LinkedInlinkedin.com/company/cavac1

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Choong Ang Vaccine Laboratories (CAVAC)